Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: Experience on 142 patients

Pier Luigi Zinzani, Cinzia Pellegrini, Alessandro Broccoli, Beatrice Casadei, Lisa Argnani, Stefano Pileri

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

There is no international consensus on front-line optimal chemotherapy regimen for advanced stage follicular lymphoma (FL) patients, or a clear definition of cure for this disease. Aim of this study was to test the degree of effectiveness and the safety of the regimen containing fludarabine, mitoxantrone, and rituximab in a subset of poor prognosis FL patients with particular focus on the long-term disease-free survival. A retrospective study was conducted on 142 intermediate/high-risk FL patients treated in first-line with fludarabine, mitoxantrone, and rituximab regimen. Responses, safety, and survival were evaluated. The prognostic value of positron emission tomography (PET) was also investigated in a 56-patients subset. Overall response rate was 95.5% including 88% of complete responses. With a median follow-up of 48 months, 18% of patients had disease relapse, yielding an estimated 12-year disease-free survival (DFS) of 72%. All cases showed the lymphoma recurrence within 40 months: after this timing the DFS curve presented a plateau. Overall survival was 73% at 12 years. Post-treatment PET positivity remains a highly significant predictor of disease progression. The observed high rate of complete responses following the use of fludarabine, mitoxantrone-based regimen in combination with rituximab seems to be the first step to improve DFS. Our study could be the starting point to consider DFS as a potential alternative endpoint of future clinical trials on FL patients. Am. J. Heamtol. 88:E273-E276, 2013.

Original languageEnglish
JournalAmerican Journal of Hematology
Volume88
Issue number11
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Mitoxantrone
Follicular Lymphoma
Non-Hodgkin's Lymphoma
Disease-Free Survival
Positron-Emission Tomography
Safety
Recurrence
Survival
Disease Progression
fludarabine
Rituximab
Lymphoma
Retrospective Studies
Clinical Trials
Drug Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma : Experience on 142 patients. / Zinzani, Pier Luigi; Pellegrini, Cinzia; Broccoli, Alessandro; Casadei, Beatrice; Argnani, Lisa; Pileri, Stefano.

In: American Journal of Hematology, Vol. 88, No. 11, 11.2013.

Research output: Contribution to journalArticle

Zinzani, Pier Luigi ; Pellegrini, Cinzia ; Broccoli, Alessandro ; Casadei, Beatrice ; Argnani, Lisa ; Pileri, Stefano. / Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma : Experience on 142 patients. In: American Journal of Hematology. 2013 ; Vol. 88, No. 11.
@article{8160f55ace6540a1b94a60e088026435,
title = "Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: Experience on 142 patients",
abstract = "There is no international consensus on front-line optimal chemotherapy regimen for advanced stage follicular lymphoma (FL) patients, or a clear definition of cure for this disease. Aim of this study was to test the degree of effectiveness and the safety of the regimen containing fludarabine, mitoxantrone, and rituximab in a subset of poor prognosis FL patients with particular focus on the long-term disease-free survival. A retrospective study was conducted on 142 intermediate/high-risk FL patients treated in first-line with fludarabine, mitoxantrone, and rituximab regimen. Responses, safety, and survival were evaluated. The prognostic value of positron emission tomography (PET) was also investigated in a 56-patients subset. Overall response rate was 95.5{\%} including 88{\%} of complete responses. With a median follow-up of 48 months, 18{\%} of patients had disease relapse, yielding an estimated 12-year disease-free survival (DFS) of 72{\%}. All cases showed the lymphoma recurrence within 40 months: after this timing the DFS curve presented a plateau. Overall survival was 73{\%} at 12 years. Post-treatment PET positivity remains a highly significant predictor of disease progression. The observed high rate of complete responses following the use of fludarabine, mitoxantrone-based regimen in combination with rituximab seems to be the first step to improve DFS. Our study could be the starting point to consider DFS as a potential alternative endpoint of future clinical trials on FL patients. Am. J. Heamtol. 88:E273-E276, 2013.",
author = "Zinzani, {Pier Luigi} and Cinzia Pellegrini and Alessandro Broccoli and Beatrice Casadei and Lisa Argnani and Stefano Pileri",
year = "2013",
month = "11",
doi = "10.1002/ajh.23540",
language = "English",
volume = "88",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma

T2 - Experience on 142 patients

AU - Zinzani, Pier Luigi

AU - Pellegrini, Cinzia

AU - Broccoli, Alessandro

AU - Casadei, Beatrice

AU - Argnani, Lisa

AU - Pileri, Stefano

PY - 2013/11

Y1 - 2013/11

N2 - There is no international consensus on front-line optimal chemotherapy regimen for advanced stage follicular lymphoma (FL) patients, or a clear definition of cure for this disease. Aim of this study was to test the degree of effectiveness and the safety of the regimen containing fludarabine, mitoxantrone, and rituximab in a subset of poor prognosis FL patients with particular focus on the long-term disease-free survival. A retrospective study was conducted on 142 intermediate/high-risk FL patients treated in first-line with fludarabine, mitoxantrone, and rituximab regimen. Responses, safety, and survival were evaluated. The prognostic value of positron emission tomography (PET) was also investigated in a 56-patients subset. Overall response rate was 95.5% including 88% of complete responses. With a median follow-up of 48 months, 18% of patients had disease relapse, yielding an estimated 12-year disease-free survival (DFS) of 72%. All cases showed the lymphoma recurrence within 40 months: after this timing the DFS curve presented a plateau. Overall survival was 73% at 12 years. Post-treatment PET positivity remains a highly significant predictor of disease progression. The observed high rate of complete responses following the use of fludarabine, mitoxantrone-based regimen in combination with rituximab seems to be the first step to improve DFS. Our study could be the starting point to consider DFS as a potential alternative endpoint of future clinical trials on FL patients. Am. J. Heamtol. 88:E273-E276, 2013.

AB - There is no international consensus on front-line optimal chemotherapy regimen for advanced stage follicular lymphoma (FL) patients, or a clear definition of cure for this disease. Aim of this study was to test the degree of effectiveness and the safety of the regimen containing fludarabine, mitoxantrone, and rituximab in a subset of poor prognosis FL patients with particular focus on the long-term disease-free survival. A retrospective study was conducted on 142 intermediate/high-risk FL patients treated in first-line with fludarabine, mitoxantrone, and rituximab regimen. Responses, safety, and survival were evaluated. The prognostic value of positron emission tomography (PET) was also investigated in a 56-patients subset. Overall response rate was 95.5% including 88% of complete responses. With a median follow-up of 48 months, 18% of patients had disease relapse, yielding an estimated 12-year disease-free survival (DFS) of 72%. All cases showed the lymphoma recurrence within 40 months: after this timing the DFS curve presented a plateau. Overall survival was 73% at 12 years. Post-treatment PET positivity remains a highly significant predictor of disease progression. The observed high rate of complete responses following the use of fludarabine, mitoxantrone-based regimen in combination with rituximab seems to be the first step to improve DFS. Our study could be the starting point to consider DFS as a potential alternative endpoint of future clinical trials on FL patients. Am. J. Heamtol. 88:E273-E276, 2013.

UR - http://www.scopus.com/inward/record.url?scp=84886314047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886314047&partnerID=8YFLogxK

U2 - 10.1002/ajh.23540

DO - 10.1002/ajh.23540

M3 - Article

C2 - 23843267

AN - SCOPUS:84886314047

VL - 88

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 11

ER -